BPC-157 for nerve damege

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • liftsiron
    Administrator
    • Nov 2003
    • 18435

    BPC-157 for nerve damege

    US National Library of Medicine National Institutes of Health


    Format: Abstract

    Send to
    Regul Pept. 2010 Feb 25;160(1-3):33-41. doi: 10.1016/j.regpep.2009.11.005. Epub 2009 Nov 10.
    Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.
    Gjurasin M1, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P.
    Author information
    Abstract

    We focused on the healing of rat transected sciatic nerve and improvement made by stable gastric pentadecapeptide BPC 157 (10 microg, 10ng/kg) applied shortly after injury (i) intraperitoneally/intragastrically/locally, at the site of anastomosis, or after (ii) non-anastomozed nerve tubing (7 mm nerve segment resected) directly into the tube. Improvement was shown clinically (autotomy), microscopically/morphometrically and functionally (EMG, one or two months post-injury, walking recovery (sciatic functional index (SFI)) at weekly intervals). BPC 157-rats exhibited faster axonal regeneration: histomorphometrically (improved presentation of neural fascicles, homogeneous regeneration pattern, increased density and size of regenerative fibers, existence of epineural and perineural regeneration, uniform target orientation of regenerative fibers, and higher proportion of neural vs. connective tissue, all fascicles in each nerve showed increased diameter of myelinated fibers, thickness of myelin sheet, number of myelinated fibers per area and myelinated fibers as a percentage of the nerve transected area and the increased blood vessels presentation), electrophysiologically (increased motor action potentials), functionally (improved SFI), the autotomy absent. Thus, BPC 157 markedly improved rat sciatic nerve healing.

    Copyright 2009 Elsevier B.V. All rights reserved.

    PMID:
    19903499
    DOI:
    10.1016/j.regpep.2009.11.005

    [Indexed for MEDLINE]
    ADMIN/OWNER@Peak-Muscle
  • liftsiron
    Administrator
    • Nov 2003
    • 18435

    #2
    Journal ListCurr Neuropharmacolv.14(8); 2016 NovPMC5333585

    Logo of currneuro
    Curr Neuropharmacol. 2016 Nov; 14(8): 857–865.
    Published online 2016 Nov. doi: 10.2174/1570159X13666160502153022
    PMCID: PMC5333585
    Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
    Predrag Sikiric,1,* Sven Seiwerth,1 Rudolf Rucman,1 Danijela Kolenc,1 Lovorka Batelja Vuletic,1 Domagoj Drmic,1 Tihomir Grgic,1 Sanja Strbe,1 Goran Zukanovic,1 Dalibor Crvenkovic,1 Goran Madzarac,1 Iva Rukavina,1 Mario Sucic,1 Marko Baric,1 Neven Starcevic,1 Zoran Krstonijevic,1 Martina Lovric Bencic,1 Igor Filipcic,1 Dinko Stancic Rokotov,1 and Josipa Vlainic2
    Author information ► Article notes ► Copyright and License information ►
    This article has been cited by other articles in PMC.
    Go to:
    Abstract
    Background

    Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice.
    Methods

    Review of our research on BPC 157 in terms of brain-gut axis.
    Results

    BPC 157 may serve as a novel mediator of Robert’s cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated. Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides, BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries.
    Conclusion

    BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.
    Keywords: Brain-gut axis, CNS-disorders, Stable gastric pentadecapeptide BPC 157, Therapy
    ADMIN/OWNER@Peak-Muscle

    Comment

    Working...